TA1018 · cancer_drugs_fund

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis [ID1501]

Recommended for Cancer Drugs Fund

Source documents

Final Appraisal DocumentCommittee PapersScopeScope Consultation Comments

Intervention

fedratinib

Conditions

primary myelofibrosishaematology · metastatic
post-polycythaemia vera myelofibrosishaematology · metastatic
post-essential thrombocythaemia myelofibrosishaematology · metastatic
primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (post-pv mf), or post-essential thrombocythemia myelofibrosis (post-et mf) with disease-related splenomegaly or symptomshaematology · relapsed_refractory

Comparators

NameType Established Committee preferred
best available therapystandard of care——
best available therapy (bat)standard of care——

Clinical trials

TrialDesignPhasePivotal
FREEDOM 2RCT—Yes

Evidence gaps

immature overall survival—Whether fedratinib extends overall survival compared to best available therapy
other—Overall survival for those on best available therapy

Commercial arrangement

managed access agreement

Special considerations

Cancer Drugs Fund eligible